Physician profile
Jeffrey Mitchel
NPI 1033126735
$6,983.89
in general payments reported to CMS, 2019-2025
44 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $1,198 · 2021: $1,128 · 2022: $1,670 · 2023: $961 · 2024: $525 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,761.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,040.31 | 2022-2025 | Micra, Aurora Ev-Icd Mri Surescan, Azure Xt Dr Mri Surescan |
| Amgen INC. | $1,024.81 | 2019-2025 | Repatha, Krystexxa |
| Medtronic Vascular, INC. | $483.39 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $460.86 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $394.04 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $391.42 | 2019-2023 | Camzyos, Eliquis |
| Pfizer INC. | $387.27 | 2019-2025 | |
| Boston Scientific Corporation | $277.52 | 2019-2024 | Emblem Mri S-Icd |
| Merck Sharp & Dohme LLC | $266.24 | 2021-2025 | Verquvo, Steglatro, Belsomra |
| Amarin Pharma, INC. | $256.86 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $240.30 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $200.01 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $161.76 | 2019-2021 | |
| Esperion Therapeutics, INC. | $147.23 | 2020-2024 | Nexletol |
| Arbor Pharmaceuticals, INC. | $143.04 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Mitchel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.